Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus...

Por Deng, Rong, Wang, Yehong, Maia, Mauricio, Burgess, Tracy, McBride, Jacqueline M., Liao, X. Charlene, Tavel, Jorge A., Hanley, William D.
Publicado no Antimicrob Agents Chemother (2018)

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

Por Hanley, William D., Wenning, Larissa A., Moreau, Allison, Kost, James T., Mangin, Eric, Shamp, Trisha, Stone, Julie A., Gottesdiener, Keith M., Wagner, John A., Iwamoto, Marian
Publicado em 2009

Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women

Por Anderson, Matt S, Hanley, William D, Moreau, Allison R, Jin, Bo, Bieberdorf, Frederick A, Kost, James T, Wenning, Larissa A, Stone, Julie A, Wagner, John A, Iwamoto, Marian
Publicado em 2011

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics

Por Iwamoto, Marian, Hanley, William D., Petry, Amelia S., Friedman, Evan J., Kost, James T., Breidinger, Sheila A., Lasseter, Kenneth C., Robson, Richard, Lunde, Norman M., Wenning, Larissa A., Stone, Julie A., Wagner, John A.
Publicado em 2009

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

Por Avery, Robert L., Castellarin, Alessandro A., Steinle, Nathan C., Dhoot, Dilsher S., Pieramici, Dante J., See, Robert, Couvillion, Stephen, Nasir, Ma'an A., Rabena, Melvin D., Maia, Mauricio, Van Everen, Sherri, Le, Kha, Hanley, William D.
Publicado no Retina (2017)

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

Por Wenning, Larissa A., Hanley, William D., Brainard, Diana M., Petry, Amelia S., Ghosh, Kalyan, Jin, Bo, Mangin, Eric, Marbury, Thomas C., Berg, Jolene K., Chodakewitz, Jeffrey A., Stone, Julie A., Gottesdiener, Keith M., Wagner, John A., Iwamoto, Marian
Publicado em 2009

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Por Fayette, Jérôme, Wirth, Lori, Oprean, Cristina, Udrea, Anghel, Jimeno, Antonio, Rischin, Danny, Nutting, Christopher, Harari, Paul M., Csoszi, Tibor, Cernea, Dana, O’Brien, Paul, Hanley, William D., Kapp, Amy V., Anderson, Maria, Penuel, Elicia, McCall, Bruce, Pirzkall, Andrea, Vermorken, Jan B.
Publicado no Front Oncol (2016)